Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMODK2J)

Drug Name

BMS-193884 Drug Info

Synonyms

BMS-193884; UNII-7ON53PV45J; CHEMBL24461; 7ON53PV45J; 176960-47-7; SCHEMBL4204130; BDBM50091105; (1,1'-Biphenyl)-2-sulfonamide, N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-; LS-44539; L001532; 4''-Oxazol-2-yl-biphenyl-2-sulfonicacid(3,4-dimethyl-isoxazol-5-yl)-amide; 4''-Oxazol-2-yl-biphenyl-2-sulfonic acid (3,4-dimethyl-isoxazol-5-yl)-amide; 4''''-Oxazol-2-yl-biphenyl-2-sulfonic acid (3,4-dimethyl-isoxazol-5-yl)-amide

Indication

Disease Entry	ICD 11	Status	REF
Pulmonary arterial hypertension	BB01.0	Discontinued in Phase 2	[1]

Cross-matching ID

PubChem CID: 9843631
CAS Number: CAS 176960-47-7
TTD Drug ID: DMODK2J

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Endothelin A receptor (EDNRA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[3]
Ambrisentan	DMD1QXW	Pulmonary arterial hypertension	BB01.0	Approved	[4]
Macitentan	DMP79A1	Cardiovascular disease	BA00-BE2Z	Approved	[5]
Sparsentan	DMMP51W	IgA nephropathy	MF8Y	Approved	[6]
LU302146	DMMJVXZ	Pulmonary hypertension	BB01	Approved	[7]
Atrasentan	DMM74PK	Diabetic nephropathy	GB61.Z	Phase 3	[8]
Clazosentan	DMQSBX4	Cerebral vasospasm	BA85.Z	Phase 3	[9]
PF-1228305	DMS1EQ7	Pulmonary hypertension	BB01	Phase 3	[10]
Darusentan	DMN8DQH	Hypotension	BA20-BA21	Phase 3	[11]
BQ-123	DM0MO8I	Pulmonary arterial hypertension	BB01.0	Phase 2	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Endothelin A receptor (EDNRA)	TTKRD0G	EDNRA_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007870)
2	Vasodilator effects of the endothelin ETA receptor selective antagonist BMS-193884 in healthy men
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
5	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
6	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
7	Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy. Clin Sci (Lond). 2002 Aug;103 Suppl 48:276S-279S.
8	Effects of a selective ET(A)-receptor antagonist, atrasentan (ABT-627), in murine models of allergic asthma: demonstration of mouse strain specificity. Clin Sci (Lond). 2002 Aug;103 Suppl 48:367S-370S.
9	Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subar... Acta Neurochir (Wien). 2007;149(9):911-8; discussion 918.
10	Pfizer. Product Development Pipeline. March 31 2009.
11	Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats. J Cardiovasc Pharmacol. 2006 Mar;47(3):456-62.
12	Endothelin in heart failure: a promising therapeutic target Heart. 1997 Feb;77(2):93-4.